Results 171 to 180 of about 344,235 (293)

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Prognostic significance of cytotoxic-T-lymphocytes to immunosuppressive lymphocytes ratio (CIL) in laryngeal squamous cell carcinoma. [PDF]

Cancer Immunol Immunother
Zhang D, Heng Y, Jin QY, Tang D, Zhu XK, Lu LM, Wu CP, Tao L.   +7 more
europepmc   +1 more source

A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes. [PDF]

Cell Death Dis, 2023
Yang W, Pang Y, Wang X, Lai Z, Lu Y, Zheng S, Wang W.   +6 more
europepmc   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study. [PDF]

Int J Mol Sci
Jo T, Saburi Y, Masunari T, Noguchi K, Sakai T, Taguchi J, Ohtsuka E, Sezaki N, Kubota-Koketsu R, Kiguchi T.   +9 more
europepmc   +1 more source

Expansion of CD4+ cytotoxic T lymphocytes with specific gene expression patterns may contribute to suppression of tumor immunity in oral squamous cell carcinoma: single-cell analysis and in vitro experiments. [PDF]

Front Immunol, 2023
Chen H, Sameshima J, Yokomizo S, Sueyoshi T, Nagano H, Miyahara Y, Sakamoto T, Fujii S, Kiyoshima T, Guy T, Nakamura S, Moriyama M, Kaneko N, Kawano S.   +13 more
europepmc   +1 more source

Identification of murine H-2Db histocompatibility antigens in cells transfected with cloned H-2 genes [PDF]

, 1985
Ferluga, J., Festenstein, H., Schmidt, Walter, Weiss, Elisabeth H.   +3 more
core   +1 more source

A Mitochondria‐Specific Nanomedicine for Synergistic Chemo‐Photothermal Therapy and Immunogenic Activation Against Breast Cancer

Advanced Science, EarlyView.
Peptide dendrimer–based nanoplatform with mitochondria‐targeting capability was developed for synergistic chemo‐photothermal therapy. The system promotes efficient transcytosis, induces mitochondrial dysfunction, triggers immunogenic cell death (ICD), and enhance antitumor immunity by promoting dendritic cell maturation and T‐cell activation, resulting
Min Li, Jiangqi Feng, Junyang Zhuang, Qingguo Zhong, Yanda Li, Yanzhuo Lv, Shaoteng Huang, Xiangyu Huang, Mingbo Zhang, Xiaofeng Cai, Yuxin Wang, Wenping Chen, Zhenyu Duan, Zhou Chen, Kui Luo, Ning Li   +15 more
wiley   +1 more source

Ruxolitinib Modulates P-Glycoprotein Function, Delays T Cell Activation, and Impairs CCL19 Chemokine-Directed Migration in Human Cytotoxic T Lymphocytes. [PDF]

Int J Mol Sci
Biwott K, Lkhamkhuu A, Ghaffar N, Papp AB, Tarban N, Goda K, Bacso Z.   +6 more
europepmc   +1 more source

Co-administration of chicken IL-2 alleviates clinical signs and replication of the ILTV chicken embryo origin vaccine by pre-activating natural killer cells and cytotoxic T lymphocytes. [PDF]

J Virol, 2023
Hao X, Li J, Wang J, Zhou Z, Yuan X, Pan S, Zhu J, Zhang F, Yin S, Yang Y, Hu S, Shang S.   +11 more
europepmc   +1 more source